ReviewTopics in antiviral medicine2023
Doxycycline postexposure prophylaxis for prevention of sexually transmitted infections.
Review in Topics in antiviral medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Phenotypic and genotypic characterization ofJAC-antimicrobial resistance · 2026Article
- When scientific constraints and real-world implementation collide: Lessons from a hybrid type 3 study of a digital, direct-to-consumer HIV prevention program.Research square · 2026Article
- Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Depression and quality of life among Thai and migrant sex workers in Thailand: a cross-sectional study.Journal of affective disorders · 2026Article
- Sexually transmitted enteric infections in men who have sex with men.Clinical microbiology reviews · 2025Review
- Interest and disparities in awareness and uptake of doxycycline postexposure prophylaxis among US MSM with HIV.AIDS (London, England) · 2025Article
- From Cure to Prevention: Doxycycline's Potential in Prophylaxis for Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2024Review
- National technical guidelines on sexually transmitted infections and reproductive tract infections (2024): Summary of updated recommendations from the National AIDS and STD Control Program in India.Indian journal of sexually transmitted diseases and AIDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxycycline postexposure prophylaxis (doxy-PEP) is a novel strategy now demonstrated in several clinical trials to dramatically reduce incidence rates of gonorrhea, chlamydia, and syphilis in some key populations at high risk of sexually transmitted infections. Even so, much remains unknown about the long-term consequences of doxy-PEP, and several concerns, including the potential for the development of antibiotic resistance and disturbances to the microbiome, balance the benefits. This review highlights the history of antibiotic prophylaxis for sexually transmitted infections, and the rationale, current evidence, and future directions for doxy-PEP.
Indexed as
Identifiers
38198668PMC10776032W4390791462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.